Published on 22 Jan 2024 on Zacks via Yahoo Finance
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why
Syros Pharmaceuticals, Inc. SYRS shares have skyrocketed 200% in the past three months compared with the industry’s rise of 13.1%.
This clinical-stage company is developing its pipeline candidate, tamibarotene, an oral, selective, retinoic acid receptor alpha or RARα agonist as a frontline treatment of acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Earlier this month, the company outlined key strategic priorities for 2024 related to the development of tamibarotene and issued a guidance.